TODAY'S ASIA TECH: Hyundai, vivo, LG
Feb.5,2024

Japanese drugmaker Eisai plans to launch Alzheimer's drug Leqembi in China by September this year, according to Reuters.

An Eisai spokesperson told Reuters that the company expects to start using the drug in China by September and forecast a total of 1,500 patients in the country by March 2025.

South Korea's Hyundai Motor Co. mulls up to $5.6 billion listing of its Indian unit, according to the Economic Times.

Leading global investment banks, including Goldman Sachs, Citi, Morgan Stanley and JP Morgan, gathered in Seoul last week to make IPO pitches to Hyundai's leadership, sources said.

The bankers valued Hyundai Motor India Ltd. (HMIL), Hyundai Motor's Indian subsidiary, at between $22 billion and $28 billion, they said.

Chinese smartphone maker vivo and Finnish telecom giant Nokia Corp. announced on Monday that they have signed a multi-year 5G patent deal, ending their legal fights globally.

Australia's competition regulator on Monday issued a proposed compulsory recall of unsafe LG solar storage batteries.

Up to 5,000 LG solar batteries in question remain in Australian homes that could overheat and catch fire without warning, according to a statement from the Australian Competition and Consumer Commission (ACCC).

Chinese video live-streaming platform DouYu International Holdings Ltd. (Nasdaq: DOYU), whose founder was arrested on criminal charges, has denied plans to merge with peer HUYA Inc. (NYSE: HUYA).

Related Topics

You must be login to post a comment.